These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Characterization of extended spectrum β-lactamase-producing Escherichia coli in community-acquired urinary tract infections in Tunisia. Hammami S; Saidani M; Ferjeni S; Aissa I; Slim A; Boutiba-Ben Boubaker I Microb Drug Resist; 2013 Jun; 19(3):231-6. PubMed ID: 23363379 [TBL] [Abstract][Full Text] [Related]
50. Prevalence of extended-spectrum beta-lactamase producing Escherichia coli in community-onset urinary tract infections in France in 2013. Martin D; Fougnot S; Grobost F; Thibaut-Jovelin S; Ballereau F; Gueudet T; de Mouy D; Robert J; J Infect; 2016 Feb; 72(2):201-6. PubMed ID: 26702736 [TBL] [Abstract][Full Text] [Related]
51. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687 [TBL] [Abstract][Full Text] [Related]
52. Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Esteve-Palau E; Grau S; Herrera S; Sorlí L; Montero M; Segura C; Durán X; Horcajada JP Rev Esp Quimioter; 2018 Apr; 31(2):110-117. PubMed ID: 29521484 [TBL] [Abstract][Full Text] [Related]
53. Prevalence and patient related factors associated with Extended-Spectrum Beta-Lactamase producing Escherichia coli and Klebsiella pneumoniae carriage and infection among pediatric patients in Tanzania. Letara N; Ngocho JS; Karami N; Msuya SE; Nyombi B; Kassam NA; Skovbjerg S; Åhren C; Philemon R; Mmbaga BT Sci Rep; 2021 Nov; 11(1):22759. PubMed ID: 34815472 [TBL] [Abstract][Full Text] [Related]
54. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. Toner L; Papa N; Aliyu SH; Dev H; Lawrentschuk N; Al-Hayek S World J Urol; 2016 Jul; 34(7):1031-7. PubMed ID: 26511749 [TBL] [Abstract][Full Text] [Related]
55. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections]. Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918 [TBL] [Abstract][Full Text] [Related]
56. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420 [TBL] [Abstract][Full Text] [Related]
57. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Ena J; Arjona F; Martínez-Peinado C; López-Perezagua Mdel M; Amador C Urology; 2006 Dec; 68(6):1169-74. PubMed ID: 17169640 [TBL] [Abstract][Full Text] [Related]
58. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years. Aris P; Boroumand MA; Rahbar M; Douraghi M Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348 [TBL] [Abstract][Full Text] [Related]
59. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases. Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487 [TBL] [Abstract][Full Text] [Related]
60. Antimicrobial Resistance in Bacteria Causing Urinary Tract Infections. Salh KK Comb Chem High Throughput Screen; 2022; 25(7):1219-1229. PubMed ID: 34161207 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]